Étude de l'innocuité, de la tolérabilité et des résultats cliniques d'Egaten chez les patients atteints de fasciolose (6 ans ou plus).
Une étude ouverte multicentrique de phase IV visant à déterminer l'innocuité, la tolérabilité et les résultats cliniques après l'administration orale d'EGATEN™ (triclabendazole) chez des patients (âgés de 6 ans ou plus) atteints de fasciolose.
The study evaluated safety and tolerability along with clinical outcomes of Egaten administered as per the FDA approved dosing regimen of 2 doses of 10 mg/kg (given approximately 12 hours apart) in Fascioliasis participants (≥ 6 years of age).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This was an open-label, single-arm, multi-center multi-country, non-comparative study planned in adult and pediatric participants (≥ 6 years of age) with acute or chronic fascioliasis.
Screening/Baseline: Screening and baseline assessments were performed as per protocol.
Treatment phase: Enrolled participants were treated with two doses of 10 mg/kg triclabendazole given approximately 12 hours apart, with the first dose administered on Day 1 under site study team's supervision. The second dose was either taken at home (self-administered) or administered at the site.
Follow-up phase: Post-treatment at Day 3 and Day 6, the enrolled participants were followed for safety and tolerability. These visits were conducted by telephone, through home visits by qualified personnel, or through onsite visits, based on the investigator's discretion. During the post treatment study site visits at Day 10, Day 30, Day 60, and Day 90 (EOS visit), the enrolled participants were followed for safety, tolerability, and efficacy. On Day 15, Day 45, and Day 75, telephonic follow ups (primarily for safety) were conducted.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Antioquia
-
Medellín, Antioquia, Colombie, 050010
- Novartis Investigative Site
-
-
-
-
-
Alexandria, Egypte, 21131
- Novartis Investigative Site
-
-
Egypt
-
Cairo, Egypt, Egypte, 11617
- Novartis Investigative Site
-
-
-
-
-
Cusco, Pérou, 08002
- Novartis Investigative Site
-
-
Lima region
-
San Martín de Porres, Lima region, Pérou, 15102
- Novartis Investigative Site
-
-
-
-
-
Sur, Turquie (Türkiye), 21280
- Novartis Investigative Site
-
Van, Turquie (Türkiye), 65080
- Novartis Investigative Site
-
-
Fatih
-
Istanbul, Fatih, Turquie (Türkiye), 34093
- Novartis Investigative Site
-
-
Sehitkamil
-
Gaziantep, Sehitkamil, Turquie (Türkiye), 27310
- Novartis Investigative Site
-
-
-
-
Binh Dinh
-
Qui Nhon, Binh Dinh, Viêt Nam, 590000
- Novartis Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Written informed consent must be obtained before any study protocol specific assessment is performed.
- Parental/legal guardian informed consent must be obtained and signed for pediatric subjects prior to any study related procedure.
- Subjects < 18 years old, who are capable of providing assent, must provide assent with parental/legal guardian consent or as per local ethical guidelines.
- If the subject is unable to read and write or otherwise incapable of signing an informed consent, then a witnessed consent according to local ethical standards is permitted.
-
Subjects (Adult and pediatric subjects ≥ 6 years of age and above 12.5 kg of weight) at time of consenting must have been diagnosed with fascioliasis based on clinical signs, symptoms and laboratory evaluations as per local clinical practice.
Exclusion Criteria:
-
Subjects diagnosed with ectopic fascioliasis, extrahepatic involvement (e.g., lungs, spleen, pancreas, subcutaneous tissue, gastrointestinal organs, etc.).
-
Subjects with known hypersensitivity to triclabendazole /other benzimidazole derivatives and/or any of the excipients in Egaten.
-
Subjects taking any anthelmintic medications within two weeks or 5 half-lives, whichever is longer prior to enrolling into study.
-
Inability or unwillingness to undergo study related procedures.
-
Subjects who in the judgment of the Clinical Investigator are unsuitable for the trial or who have to be excluded in order to be compliant with local fascioliasis management guidelines that may differ from the FDA approved label, including but not limited to :
- Subjects who are machine operators or drivers.
- Medical history of liver (other than fascioliasis), kidney or cardiac disease.
-
Females (including under the age of 18) known to be pregnant or testing positive for pregnancy at screening.
-
Lactating women unwilling to discontinue lactation up to 72 hours after the second dose administration or as per local guidelines.
-
Subjects requiring therapeutic drug monitoring of CYP2C19 substrate(s) (e.g. S-mephenytoin).
-
Subjects with medical history of QT prolongation or a history of symptoms compatible with a long QT interval or on medication which prolong the QT interval.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Egaten
Triclabendazole was administered as two 10 mg/kg doses given approximately 12 hours apart. Both doses were administered orally with food. |
Egaten 250 mg scored tablets for oral use.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: Adverse events were reported from the first dose of study treatment until approximately 90 days thereafter.
|
Number of participants with treatment emergent adverse events (any AE regardless of seriousness), and SAEs. |
Adverse events were reported from the first dose of study treatment until approximately 90 days thereafter.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Acute and Chronic Fascioliasis Participants Who Achieved Clinical Response
Délai: Baseline, Day 10
|
Clinical Response at Day 10 was defined as improvement or resolution of baseline signs and symptoms. 95% confidence interval (CI) is calculated based on Clopper-Pearson method. |
Baseline, Day 10
|
|
Percentage of Acute Fascioliasis Participants Who Achieved Clinical Cure
Délai: Baseline, Day 30, Day 60 and Day 90
|
A participant was considered to achieve clinical cure if all of the following criteria were met.
Abdomen - for hepatic lesions and/or biliary tract blockage caused by Fasciola worm(s) • Improvement in the lab parameter from baseline: Eosinophil count: ≥ 50% reduction from baseline value or reaching normal range if baseline value was above normal range 95% confidence interval (CI) is calculated based on Clopper-Pearson method. |
Baseline, Day 30, Day 60 and Day 90
|
|
Percentage of Chronic Fascioliasis Participants Who Achieved Clinical Cure
Délai: Baseline, Day 30, Day 60 and Day 90
|
A participant was considered to achieve clinical cure if all of the following criteria were met.
Eosinophil count: ≥50% reduction from baseline or reaching normal range if baseline value was above normal range Hemoglobin: ≥1 g/dL increase from baseline value or reaching normal range if baseline value was below normal range Liver function test: ≥1 grade improvement from baseline or reaching normal range for each test if baseline value was above normal range Erythrocyte sedimentation rate: ≥ 50% reduction from baseline or reaching normal range if baseline value was above normal range 95% CI is calculated based on Clopper-Pearson method. |
Baseline, Day 30, Day 60 and Day 90
|
|
Percentage of Chronic Fascioliasis Participants Who Achieved Parasitological Cure
Délai: At Day 10, Day 30, Day 60 and Day 90
|
The parasitological cure rate in chronic fascioliasis participants was measured by the proportion of participants with absence of fasciola eggs confirmed by stool examination. In case of missing assessments at post baseline visits, parasitological cure is imputed as cured if two consecutive prior visits are negative, else parasitological cure is imputed as not cured. 95% confidence interval (CI) is calculated based on Clopper-Pearson method. |
At Day 10, Day 30, Day 60 and Day 90
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CEGA230B2404
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .